Larin 1/20

Quick links to important sections

Larin 1/20

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Larin 1/20

Quick Facts

Property Description
Active ingredient Norethindrone acetate, Ethinyl estradiol
Form Oral Tablets
Pharmacological class Combined Oral Contraceptive (COC), Sex Hormone Combinations
Common use Pregnancy prevention (Contraception)
Origin Synthetic (hormonal compounds)

Identity and Pharmacological Class

Larin 1/20 is accurately defined as a Combined Oral Contraceptive (COC), which places it within the broader Sex Hormone Combinations pharmacological class. This oral preparation is fundamentally a synthetic combination product intended for pregnancy prevention in women of reproductive potential, a use that is broadly and clinically recognized across international health guidelines. The classification as a COC indicates the drug contains both an estrogen and a progestin compound, which work together to regulate the reproductive cycle. As a pharmaceutical entity, its general utility is centered strictly on fulfilling this specific therapeutic use. Larin 1/20 is a brand name, but its core formulation of Norethindrone acetate and Ethinyl estradiol is shared by several established generic equivalents, affirming its role in hormonal therapy.

Composition and Hormonal Characteristics

The active ingredients in Larin 1/20 are Norethindrone acetate and Ethinyl estradiol. Norethindrone acetate is a synthetic progestin, while Ethinyl estradiol is a potent synthetic estrogen derivative. This dual-hormone structure is essential for its function as a combination product. This specific formulation is notable for its low hormonal concentration: it is characterized as a low-dose COC due to its 20 mcg of Ethinyl estradiol. The use of this specific progestin derivative is consistent with a wide range of hormonal contraceptives available globally, highlighting the established, fact-based reliability of this type of hormonal combination for contraception. In some presentations, non-hormonal tablets containing Ferrous fumarate are included to maintain a daily pill-taking routine, but this compound does not contribute to the hormonal contraceptive effect.

What side effects are possible with Larin 1/20?

Possible Side Effects and Safety Information

The official safety profile for Larin 1/20 (Norethindrone acetate and Ethinyl estradiol) is structured by government regulatory agencies to inform on potential adverse reactions and serious risks.

Adverse Reaction Classifications

Side effects are formally classified by frequency and grouped according to the body systems they affect (System-Organ Classes). Effects classified as Most Common (occurring in ge 2% of users in clinical data) often relate to hormonal adjustment, including headache, nausea, breast tenderness, and weight gain. Other common effects include mood changes, abdominal pain, and irregular uterine bleeding.

Serious Adverse Reactions

The regulatory labeling highlights the potential for serious, though rare, thrombotic and thromboembolic events. These include Deep Vein Thrombosis (DVT), pulmonary embolism, myocardial infarction (heart attack), and stroke. The official documentation also lists the possibility of hepatic neoplasia (liver tumors, both benign and malignant) and the development of gallbladder disease.

Population-Specific Safety Constraints

The official safety information notes specific restrictions regarding use in certain groups. A major constraint documented in regulatory text is the significantly increased risk of serious cardiovascular events for smokers over 35 years old. Furthermore, the medication is contraindicated in individuals with a history of thromboembolic disorders, severe hypertension, or severe liver impairment. Safety guidance also formally states that the medication must be temporarily discontinued before and after major surgery or during prolonged immobilization to reduce the risk of blood clots. Irregular bleeding is most frequent during the first few months of use, and the risk of VTE is highest during the first year of initial treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for combination oral contraceptives, including Larin 1/20 (norethindrone acetate and ethinyl estradiol), define overdose by specific clinical manifestations and mandated emergency actions. This information serves as the basis for patient-oriented guidance on urgent care.

Documented Clinical Manifestations Overdose may present with certain non-life-threatening signs, which include the following officially noted symptoms:

  • Nausea and vomiting
  • Withdrawal bleeding (vaginal bleeding)
  • Breast tenderness or enlargement

Regulatory data indicates that acute ingestion of large doses by young children has generally not been reported to cause serious ill effects related to the hormonal components alone.

Required Emergency Actions and Treatment It is officially mandated to get medical help right away or call a poison control center immediately upon suspected overdose. Treatment is defined by the following official statements:

Action Focus Official Regulatory Statement
Antidote Status No specific antidote is known.
Treatment Treatment must be symptomatic and supportive in nature.
Procedure Gastric lavage may be considered if the ingestion is seen sufficiently early (within four hours) of a large overdose.

Critical Population-Specific Warning If the formulation contains iron (e.g., Larin Fe), the label provides a critical warning: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children younger than 6 years. This scenario requires immediate, urgent medical attention.

Therapeutic Uses of Larin 1/20

What Larin 1/20 Treats: Main Uses and Benefits

Larin 1/20 is commonly used to provide symptomatic support across several key domains of women's reproductive health, with a primary focus on continuous protection and the management of associated symptoms.

Therapeutic Scope and Key Benefits

The medication is commonly used to help with effective pregnancy prevention for women of reproductive age. This class of oral contraceptives is considered relevant for this fundamental purpose.

The medication may assist in managing symptoms that interfere with daily functioning, such as painful periods (dysmenorrhea) and excessive blood loss (menorrhagia). The medication supports the management of unpredictable monthly bleeding and contributes to easing the heavy flow and pain that may interfere with daily functioning. The formulation is also applied in addressing moderate acne vulgaris in patients seeking oral contraception.

Quick Fact: Relief for Menstrual Discomfort The medication may assist with managing symptoms associated with recurrent symptomatic episodes, which contributes to improved comfort during symptomatic periods.

Beyond symptom management, the medication may be relevant for easing the functional stress associated with recurrent ovarian cysts. The overall use provides supportive relief that may assist with managing the appearance and severity of persistent blemishes, which helps improve day-to-day comfort.

“The medication is applied across domains where additional symptomatic support is needed alongside effective, continuous protection.”

Regulatory References

  1. NIH MedlinePlus overview on Ethinyl Estradiol and Norethindrone

Eligibility and Restrictions for Use

Larin 1/20 is officially intended for use by women of reproductive potential seeking pregnancy prevention. Regulatory documents establish a comprehensive profile of absolute contraindications for populations where the associated risks outweigh the benefits of use.

Eligibility Classification

Population Status Official Regulatory Definition
Allowed Population Women of reproductive potential.
Not Recommended Nursing mothers / Women who are breastfeeding.
Contraindicated Women with a high risk of arterial or venous thrombotic diseases.

Populations Formally Contraindicated

The following conditions and populations are listed as absolute prohibitions for use, according to regulatory documents:

  • Smoking and Age: Women over age 35 who smoke.
  • Vascular/Thrombotic History: Current or history of deep vein thrombosis (DVT), pulmonary embolism (PE), cerebral vascular disease, or coronary artery disease.
  • High-Risk Comorbidities: Uncontrolled hypertension, diabetes mellitus with vascular involvement, or severe migraine headaches (particularly those with aura).
  • Hormone-Sensitive Conditions: Known or suspected breast cancer or other estrogen-sensitive neoplasia; current or history of liver tumors or active liver disease.
  • Physiological Status: Known or suspected pregnancy (contraindicated). Use is not indicated for post-menopausal women, nor should it be initiated prior to menarche.

What should I know about interactions with other medicines?

Larin 1/20 Interactions with other medicines and products

This section addresses documented interaction patterns for Larin 1/20 (Norethindrone acetate/Ethinyl estradiol) as described in official government regulatory documents.

Contraindicated Combinations

Co-administration with certain prescription drug therapies is formally prohibited:

Interacting Substance/Class Official Interaction Status
Hepatitis C combination therapies (e.g., Ombitasvir/Paritaprevir/Ritonavir pm Dasabuvir) Formally contraindicated due to risk of liver enzyme elevation.
Fezolinetant Co-administration is formally contraindicated.

Exposure-Altering Interactions

The hormonal components can interact with other medicines by altering plasma concentrations.

  • Enzyme Inducers: Several medicines, including certain Anticonvulsants (e.g., Phenytoin, Carbamazepine) and the antibiotic Rifampin, are documented to induce enzymes, which reduces the plasma concentrations of the Larin 1/20 hormones.
  • Enzyme Inhibitors: Substances such as high-dose Grapefruit Juice are noted to potentially increase the concentration of the estrogen component by inhibiting its metabolism.
  • Other Drug Levels: The estrogen component may increase the exposure of co-administered medicines, such as Caffeine, by inhibiting its clearance. Conversely, Larin 1/20 is also documented to reduce the plasma concentration of Lamotrigine.

Non-Medicinal and Component Interactions

  • Herbal Products: The herbal supplement St. John's wort is listed as an enzyme inducer that can decrease hormone concentrations.
  • Inactive Tablet Component: In Larin Fe formulations, the Ferrous fumarate (iron) in the non-hormonal tablets is officially noted to reduce the absorption of several co-administered drugs, including thyroid medications (e.g., Levothyroxine).

Population-Specific Caution

Official regulatory warnings define use in women over 35 years of age who smoke as a formal contraindication.

Mechanism of Action

The mechanism of action for Larin 1/20 is defined by the coordinated activation (agonism) of Progestin and Estrogen Receptors by Norethindrone acetate and Ethinyl estradiol. This dual-hormone agonism targets the Hypothalamic-Pituitary-Ovarian (HPO) axis, inducing a continuous negative feedback signal on the hypothalamus and pituitary gland. This central action suppresses the cyclical secretion of gonadotropins, Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH), which are necessary for the ovary's normal function, resulting in anovulation.

This central mechanism is complemented by two peripheral actions. The synthetic progestin alters the secretory structure of the cervical glands, causing the mucus to become thicker and less penetrable, thereby impeding sperm motility and penetration. Simultaneously, the combined hormones act on the endometrial lining, altering its structure to an atrophic state and resulting in an altered, less receptive morphology. The estrogen component synergistically supports the progestin's inhibitory effect on the HPO axis, ensuring that the primary mechanism of anovulation is consistently sustained.

Dosage and Administration Information

How Larin 1/20 is Used

The administration of Larin 1/20 is defined by a continuous, cyclic pattern that requires strict adherence to a daily schedule. This medication is available as oral tablets and is administered exclusively by the oral route. The primary principle governing its use is the consistent daily intake of one tablet, ensuring the interval between doses does not exceed 24 hours.

Standard Dosing and Schedule

The standard regimen involves a 28-day cycle of tablets taken daily. The dose alternates between 24 active tablets and 4 non-hormonal tablets. Each active tablet contains the fixed dose of 1 mg Norethindrone acetate and 20 mcg Ethinyl estradiol. The four non-hormonal tablets, which serve to maintain the daily routine, are taken at the end of the cycle.

Instruction Detail
Administration Route Oral (by mouth) only.
Dosing Frequency One tablet taken daily (every 24 hours).
Active Dose 1 mg Norethindrone acetate / 20 mcg Ethinyl estradiol.
Timing Condition Must be taken at the same time every day, regardless of meals.

Procedural Administration

Users must take the tablets in the precise order directed on the blister pack, beginning the cycle with one of two standard starting procedures: the Day-1 Start or the Sunday-Start. If the regimen is not initiated on the first day of the menstrual period, the established procedure requires the use of an additional non-hormonal back-up method for the first seven days of the initial cycle. The efficacy of this formulation has not been evaluated in patients with a Body Mass Index (BMI) greater than 35 kg/m^2.

Recent Clinical Evidence

Evidence for Use in Pregnancy Prevention (Contraception)

This area is supported by extensive scientific research, including Randomized Controlled Trials (RCTs) and systematic reviews, focusing on healthy women of reproductive potential. Studies aimed to measure the rate of unintended pregnancy and patterns related to consistency of use among participants. The consistent body of data reports measurements related to the primary study aim (prevention of pregnancy) and shows clear patterns related to its primary focus of research. The evidence highlights that real-world application results were observed in some studies to be influenced by consistency of use, and comparative evidence is lacking for certain long-term, non-contraceptive health outcomes when compared to non-hormonal contraceptive methods.


Evidence for Exploring Menstrual Symptoms

The combined oral contraceptive class was studied for its application in exploring symptoms related to the menstrual cycle, including painful periods (dysmenorrhea) and excessive blood loss (menorrhagia). For dysmenorrhea, RCTs examined changes in subjective pain intensity scores. Findings were mixed across various studies, sometimes due to the subjective nature of pain reporting. For menorrhagia, research explored changes in objectively measured blood loss volume, with measured values describing a change in bleeding volume over a few months of use.


Evidence for Use in Moderate Acne and Cycle Regularity

Research was conducted in patients with moderate acne vulgaris who were also participants in studies for contraception. Studies examined changes in inflammatory lesion counts and standardized assessment scales. This evidence contributes to understanding the role of combination oral contraceptives in studies of this skin condition. Separately, research describes a consistent pattern toward a predictable withdrawal bleeding schedule after the initial few cycles, though data are still emerging regarding breakthrough bleeding during the early adjustment period.


Research Gaps and Limitations

Clinical research for many secondary uses is typically restricted to shorter or intermediate time intervals (e.g., six to twelve cycles). As a result, there is limited information for long-term outcomes regarding the durability of these particular responses. Data for certain groups, particularly older women or those with pre-existing chronic conditions, remain insufficient. Furthermore, the evidence related to the management of recurrent ovarian cysts remains limited and its certainty is low.

Frequently Asked Questions (FAQ)

Common questions about Larin 1/20 (FAQ)

Q: Is there a known link between Larin 1/20 and changes in mood, anxiety, or depression?

Mood changes, including depression, are documented as possible side effects in the official product information. Regulatory documents describe that women with a history of depression should be observed with care, and that reoccurrence of serious depression requires evaluation.

Q: Is breakthrough bleeding or spotting common when first starting Larin 1/20?

Yes, irregular bleeding, spotting, or breakthrough bleeding is a documented common adverse reaction in clinical data. This is most frequently observed during the first few months of starting treatment as your body adjusts to the hormones.

Q: How long does it typically take for Larin 1/20 to become fully effective?

Official prescribing information indicates that the drug is generally considered effective after the seventh consecutive day of taking the active tablets. Regulatory documents describe that a non-hormonal back-up method is required during the first seven days of the initial cycle if the treatment is started later than the first day of the menstrual period.

Q: How is the bleeding experienced during the inactive pill week different from a natural menstrual period?

The bleeding that occurs during the inactive pill week is known as withdrawal bleeding, not a natural menstrual period. Studies and official information indicate that this bleeding is often lighter and milder in flow because the medication prevents the typical thickening of the uterine lining.

Q: Can Larin 1/20 cause or affect skin conditions like acne?

The medication is indicated for the treatment of moderate acne in women who also desire oral contraception. However, acne is also listed as a common adverse reaction in clinical trials.

Q: Can Larin 1/20 affect hair—for example, cause hair loss or increased growth?

The official adverse reaction tables do not list hair changes as a common or serious effect. However, the hormonal components may have androgenic effects which are sometimes associated with hair changes. Conversely, suppressing hormone levels through oral contraceptives can help improve symptoms like excessive hair growth associated with certain conditions.

Q: Is Larin 1/20 used for non-contraceptive purposes like managing symptoms of PCOS?

Larin 1/20 is officially indicated for pregnancy prevention only. The hormones in this type of medication, however, can help regulate the menstrual cycle and reduce androgen-related symptoms, such as acne, which are sometimes associated with other conditions like Polycystic Ovary Syndrome (PCOS).

Q: What kind of routine follow-up care or monitoring is generally recommended while taking Larin 1/20?

Regulatory guidance suggests periodic follow-up. This monitoring commonly includes checking blood pressure and performing examinations of the breasts and pelvis. Additionally, monitoring blood sugar and lipid levels is also advised for women with pre-existing conditions like diabetes or high cholesterol.

Q: What is the chance of having a completely missed period while taking the active pills?

The absence of a scheduled withdrawal bleed, known as amenorrhea, is a documented effect of hormonal contraceptives due to the thinning of the uterine lining. Regulatory documents indicate that if a period is missed during the scheduled withdrawal week, evaluation for pregnancy is advised.

Q: Does Larin 1/20 interact with common over-the-counter pain relievers like acetaminophen or ibuprofen?

Official information documents that oral contraceptives may affect the way the body processes acetaminophen (Tylenol), potentially decreasing or delaying its effect. No interaction is specifically cited in regulatory documents for the common pain reliever ibuprofen.

Q: Why does vomiting or severe diarrhea after taking a pill require a back-up method?

Severe vomiting or diarrhea can reduce the absorption of the active hormones, which may compromise the drug's effectiveness. Regulatory instructions describe that a back-up contraceptive method is required in these situations to ensure efficacy is maintained.

Q: Can Larin 1/20 cause changes in vision or affect the tolerance for contact lenses?

Hormonal contraceptives may cause issues with vision, including the inability to wear contact lenses due to changes in corneal curvature. Official safety warnings describe that sudden or unexplained vision changes are among the conditions that warrant immediate discontinuation and medical evaluation.

Q: What is melasma, and is it a possible skin-related side effect of Larin 1/20?

Melasma (blotchy, dark areas on the face and skin) is a documented potential side effect. Regulatory guidance advises limiting sun exposure and using sunscreen to reduce the risk of this effect.

Q: Does having a family history of certain cancers affect eligibility for Larin 1/20?

Official guidance advises that women with a strong family history of breast cancer or who have breast nodules should be monitored with particular care while using this medication.

Q: Is fluid retention or swelling in the feet/ankles a potential side effect of Larin 1/20?

Fluid retention or swelling is documented as a possible effect of oral contraceptives. The official safety information advises caution and monitoring for patients with conditions that may be worsened by fluid retention.

Q: What should be done if an inactive pill is accidentally skipped or missed?

The inactive tablets do not contain hormones and do not serve a therapeutic purpose. Missing an inactive tablet does not affect the drug's contraceptive effectiveness, provided that the active tablets were taken correctly and the next pack is started on time.

How should Larin 1/20 be stored and disposed of?

Official Storage and Disposal Instructions for Larin 1/20

The regulatory label mandates that Larin 1/20 tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Brief temperature excursions between 15 C and 30 C are permitted, but excessive heat should be avoided.


Storage and Handling

The product must be kept in its original blister card for protection and stored out of the reach of children. Maintaining the specific temperature range ensures the product's stability through its expiration date.

Disposal of Unused Medicine

Official disposal guidelines recommend utilizing a drug take-back program or a mail-back option for unused or expired tablets. If these options are unavailable, the FDA instructs mixing the medicine with an unappealing substance, such as dirt or coffee grounds, sealing it in a plastic bag, and then placing it in the household trash. The tablets should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Larin 1/20 found in:

A-Z Index: